Table 2 Univariate and multivariate analyses of PFS
Variable (comparator) | Progression free survival | |||
|---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Early ir-fatigue | ||||
Yes vs no | 2.25 (1.63–3.1) | < 0.0001 | 2.29 (1.62–3.22) | < 0.0001 |
Sex | ||||
Male vs female | 1.05 (0.78–1.41) | 0.7515 | – | – |
Age at diagnosis | ||||
Elderly vs non-elderly | 1.20 (0.91–1.58) | 0.1940 | – | – |
Primary tumor (melanoma) | ||||
NSCLC | 1.51 (1.09–2.08) | 0.0124 | 1.08 (0.76–1.53) | 0.6446 |
Renal cell carcinoma | 1.55 (1.06–2.28) | 0.0241 | 1.22 (0.81–1.85) | 0.3445 |
Others | 1.38 (0.43–4.40) | 0.5790 | 0.95 (0.29–3.06) | 0.9336 |
Treatment line | ||||
Non-first vs first | 1.75 (1.28–2.42) | 0.0005 | 1.66 (1.17–2.35) | 0.0041 |